Tsilika, Maria
Mitrou, John
Antonakos, Nikolaos
Tseti, Ioulia K.
Damoraki, Georgia
Leventogiannis, Konstantinos
Giamarellos-Bourboulis, Evangelos J. http://orcid.org/0000-0003-4713-3911
Funding for this research was provided by:
University of Athens
Article History
Received: 17 June 2022
Accepted: 23 March 2023
First Online: 6 April 2023
Declarations
:
: E. J. Giamarellos-Bourboulis has received honoraria from Abbott CH, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi, and XBiotech Inc; independent educational grants from Abbott CH, AxisShield, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Sobi, and XBiotech Inc.; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis). J. K. Tsetis is the CEO of Uni-Pharma SA.